Minimal Residual Disease in Acute Lymphoblastic Leukemia

Minimal residual disease in acute lymphoblastic leukemia.

In patients with acute lymphoblastic leukemia (ALL), monitoring of minimal residual disease (MRD) offers a way to precisely assess early treatment response and detect relapse. Established methods to study MRD are flow cytometric detection of abnormal immunophenotypes, polymerase chain reaction (PCR) amplification of antigen-receptor genes, and PCR amplification of fusion transcripts. The strong...

Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

MRD diagnostics during the first three months of treatment has proven to be of high value in pediatric acute lymphoblastic leukemia (ALL), because of its potential to recognize subgroups that differ substantially in outcome. Consequently, MRD diagnostics is now being used for treatment intervention, both treatment intensification (including stem cell transplantation) and treatment reduction. Ho...

Detection of minimal residual disease in acute lymphoblastic leukemia.

To detect more precisely the minimal residual disease in acute lymphoblastic leukemia (ALL), two-color flow cytometric analysis for the detection of cell-surface antigen (CD10; CALLA) and nuclear terminal deoxynucleotidyl transferase (TdT) was performed in the six patients with CALLA-positive ALL coexpressing TdT. In all patients, the leukemic blasts coexpressed Ia (HLA-DR), CD9, CD19, CD20, CD...

Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia